{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26","value":"158.3"},{"groupId":"OG001","spread":"26","value":"188.2"},{"groupId":"OG002","spread":"22","value":"200.8"},{"groupId":"OG003","spread":"38","value":"185.1"},{"groupId":"OG004","spread":"18","value":"187.4"},{"groupId":"OG005","spread":"32","value":"174.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"10"}],"units":"Participants"}],"title":"Cycle 1/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46","value":"46.74"},{"groupId":"OG001","spread":"20","value":"37.71"},{"groupId":"OG002","spread":"24","value":"39.14"},{"groupId":"OG003","spread":"24","value":"41.96"},{"groupId":"OG004","spread":"24","value":"41.32"},{"groupId":"OG005","spread":"36","value":"36.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"title":"Cycle 1/Day8-168 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20","value":"201.8"},{"groupId":"OG001","spread":"136","value":"124.1"},{"groupId":"OG002","spread":"91","value":"150.8"},{"groupId":"OG003","spread":"17","value":"167.3"},{"groupId":"OG004","spread":"20","value":"217.2"},{"groupId":"OG005","spread":"1114","value":"80.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"7"}],"units":"Participants"}],"title":"Cycle 1/Day15-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18","value":"200.4"},{"groupId":"OG001","spread":"23","value":"190.9"},{"groupId":"OG002","spread":"143","value":"149.2"},{"groupId":"OG003","spread":"42","value":"142.9"},{"groupId":"OG004","spread":"18","value":"228.5"},{"groupId":"OG005","spread":"24","value":"175.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"7"}],"units":"Participants"}],"title":"Cycle 2/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30","value":"188.9"},{"groupId":"OG001","spread":"23","value":"210.0"},{"groupId":"OG002","spread":"29","value":"193.9"},{"groupId":"OG003","spread":"6","value":"192.8"},{"groupId":"OG004","spread":"16","value":"223.2"},{"groupId":"OG005","spread":"25","value":"178.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"title":"Cycle 4/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25","value":"216.7"},{"groupId":"OG001","spread":"34","value":"198.8"},{"groupId":"OG002","spread":"13","value":"208.2"},{"groupId":"OG003","spread":"4","value":"161.0"},{"groupId":"OG004","spread":"8","value":"217.1"},{"groupId":"OG005","spread":"19","value":"193.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"title":"Cycle 6/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10","value":"203.7"},{"groupId":"OG001","spread":"53","value":"196.0"},{"groupId":"OG002","spread":"26","value":"194.5"},{"groupId":"OG003","spread":"2","value":"182.0"},{"comment":"Geometric Coefficient of Variation was not estimable as there was only 1 participant analyzed.","groupId":"OG004","spread":"NA","value":"268.0"},{"groupId":"OG005","spread":"34","value":"229.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"}],"units":"Participants"}],"title":"Cycle 10/Day1-1 Hour/EOI"}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"10"}],"units":"Participants"}],"description":"Cmax is maximum observed plasma concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 0.1 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG000","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 0.1 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 0.1 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG001","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 0.1 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 0.3 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG002","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 0.3 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG003","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 0.3 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 20 mg IV Q4W along with PF-04518600 1.0 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG004","title":"Combination D Phase 1b: Utomilumab 20 mg + PF-04518600 1.0 mg/kg + Avelumab"},{"description":"During Phase 1b participants received utomilumab 50 mg IV Q4W along with PF-04518600 1.0 mg/kg IV Q2W and 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG005","title":"Combination D Phase 1b: Utomilumab 50 mg + PF-04518600 1.0 mg/kg + Avelumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set included all participants who had received at least one dose of study drug and who had at least one of the PK concentrations of interest for Avelumab, Utomilumab, PD 0360324, PF-04518600. Here, \"Number of participants analyzed'' signifies number of participants evaluable for this outcome measure, where \"Number Analyzed\" signifies number of participants evaluable for specified time points.","reportingStatus":"POSTED","timeFrame":"1 hour post-dose (at end of infusion) on Days 1 and 15 of Cycle 1; Day 8 of Cycle 1 (non-dosing); Pre-dose and 1 hour post-dose on Day 1 of Cycle 2, 4, 6, 10","title":"Maximum Observed Plasma Concentration (Cmax) of Avelumab in Combination D","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter"}